Evidence map›Paper›PMID 38824124›Full record

ArticleNature communications2024

IκBα controls dormancy in hematopoietic stem cells via retinoic acid during embryonic development.

Roshana Thambyrajah, Maria Maqueda, Muhammad Zaki Fadlullah, Martin Proffitt, Wen Hao Neo, Yolanda Guillén, Marta Casado-Pelaez, Patricia Herrero-Molinero, Carla Brujas, Noemi Castelluccio and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Roshana ThambyrajahProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain. roshanathambyrajah@gmail.com.ORCID http://orcid.org/0000-0002-3941-760X
Maria MaquedaProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Muhammad Zaki FadlullahCancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-3111-8090
Martin ProffittProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Wen Hao NeoCancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-6827-3027
Yolanda GuillénProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Marta Casado-PelaezJosep Carreras Leukemia Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8428-8384
Patricia Herrero-MolineroProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Carla BrujasProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Noemi CastelluccioProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2635-4889
Jessica GonzálezProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7732-1564
Arnau IglesiasProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Laura MarruecosProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Cristina Ruiz-HerguidoProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.
Manel EstellerJosep Carreras Leukemia Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4490-6093
Elisabetta MereuJosep Carreras Leukemia Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6101-8472
Georges LacaudCancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-5630-2417
Lluis EspinosaProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2897-4099
Anna BigasProgram in Cancer Research, Hospital del Mar Research Institute, Barcelona, Spain. abigas@imim.es.ORCID http://orcid.org/0000-0003-4801-6899

Funding

Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (Department of Innovation, Education and Enterprise, Government of Catalonia) 2021SGR00039Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (Department of Innovation, Education and Enterprise, Government of Catalonia) BP2016(00021)Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (Department of Innovation, Education and Enterprise, Government of Catalonia) BP2018(00034)Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2019-104695RB-I00Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación) PID2022-137945OB-I00Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CA22/00011
6 · The paper itself

Abstract

Recent findings suggest that Hematopoietic Stem Cells (HSC) and progenitors arise simultaneously and independently of each other already in the embryonic aorta-gonad mesonephros region, but it is still unknown how their different features are established. Here, we uncover IκBα (Nfkbia, the inhibitor of NF-κB) as a critical regulator of HSC proliferation throughout development. IκBα balances retinoic acid signaling levels together with the epigenetic silencer, PRC2, specifically in HSCs. Loss of IκBα decreases proliferation of HSC and induces a dormancy related gene expression signature instead. Also, IκBα deficient HSCs respond with superior activation to in vitro culture and in serial transplantation. At the molecular level, chromatin regions harboring binding motifs for retinoic acid signaling are hypo-methylated for the PRC2 dependent H3K27me3 mark in IκBα deficient HSCs. Overall, we show that the proliferation index in the developing HSCs is regulated by a IκBα-PRC2 axis, which controls retinoic acid signaling.

Indexed as

Cell ProliferationHematopoietic Stem CellsNF-KappaB Inhibitor alphaSignal TransductionTretinoinAnimalsEmbryonic DevelopmentFemaleGene Expression Regulation, DevelopmentalMiceMice, Inbred C57BLMice, KnockoutPolycomb Repressive Complex 2NF-KappaB Inhibitor alphaNfkbia protein, mousePolycomb Repressive Complex 2Tretinoin

Identifiers

PMID38824124
PMCPMC11144194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.